The European Medicines Agency has started reviewing new marketing applications for 10 products, including Blenrep, GSK’s previously approved multiple myeloma drug that was withdrawn from the market, and vimseltinib, which could become the EU’s first oral treatment approved for TGCT.

“We continue to believe that taking care of your health or someone in your family is the last place to look to make a change or save a few pennies,” says CEO Ron Lombardi. Firm more frequently using air freight services so Clear Eyes products are on store shelves when consumers expect.

The company raised $120m in a series B funding round and plans to start a Phase III study of IDRX-42 next year. Scrip talked to IDRx’s execs about the company’s development strategy.

Restructuring Edition: Vir will end influenza, COVID-19 and T-cell-based viral vector platform programs to focus on clinical hepatitis and cancer assets. Also, FibroGen cut 75% of its workforce after a clinical trial failure, while Arbutus, HilleVax, Pfizer and others also announced layoffs.